LODINE XL
ETODOLAC
Approval overview LODINE XL is listed in Drugs@FDA under application 020584 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient ETODOLAC Form and strength TABLET, EXTENDED RELEASE;ORAL - 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor WYETH PHARMS INC Submission history Latest submission status date: 2006-01-18 00:00:00.
Structured Monograph
Clinical summary
Approval overview LODINE XL is listed in Drugs@FDA under application 020584 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ETODOLAC Form and strength TABLET, EXTENDED RELEASE;ORAL - 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor WYETH PHARMS INC Submission history Latest submission status date: 2006-01-18 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.